The novelty of the present study stems from the evidence that we identified for the first time the deficit of TGF-β1 pathway as an early event in PNS-induced depression that can be detected in adolescent depression and might then represent a novel pharmacological target to reduce vulnerability to adult depression. This evidence concerns the gene TGFB1 and depressive disorder.